amifampridine

Ligand id: 8032

Name: amifampridine

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 3
Hydrogen bond donors 2
Rotatable bonds 0
Topological polar surface area 64.93
Molecular weight 109.06
XLogP -0.66
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

References
1. Rees JH. (2004)
Paraneoplastic syndromes: when to suspect, how to confirm, and how to manage.
J. Neurol. Neurosurg. Psychiatr.75 Suppl 2: ii43-50. [PMID:15146039]
2. Takamori M. (2008)
Lambert-Eaton myasthenic syndrome: search for alternative autoimmune targets and possible compensatory mechanisms based on presynaptic calcium homeostasis.
J. Neuroimmunol.201-202: 145-52. [PMID:18653248]
3. Tarr TB, Lacomis D, Reddel SW, Liang M, Valdomir G, Frasso M, Wipf P, Meriney SD. (2014)
Complete reversal of Lambert-Eaton myasthenic syndrome synaptic impairment by the combined use of a K+ channel blocker and a Ca2+ channel agonist.
J. Physiol. (Lond.)592 (Pt 16): 3687-96. [PMID:25015919]
4. Verschuuren JJ, Wirtz PW, Titulaer MJ, Willems LN, van Gerven J. (2006)
Available treatment options for the management of Lambert-Eaton myasthenic syndrome.
Expert Opin Pharmacother7 (10): 1323-36. [PMID:16805718]